Trevi Therapeutics, Inc. (TRVI) Stock Analysis

Trevi Therapeutics’ principal competitive advantage lies in its lead asset, Haduvio (oral nalbuphine ER), which targets chronic cough in idiopathic pulmonary fibrosis (IPF)—a condition with no FDA-approved therapies and high unmet need. Haduvio’s dual mechanism of action (central and peripheral opioid receptor modulation) differentiates it from competitors such as Merck’s gefapixant (a P2X3 antagonist, approved for refractory chronic cough in Europe and Japan but not in the U.S.) and GSK’s camlipixant (in development). In Phase 2b, Haduvio achieved a 60% reduction in cough frequency at the highest dose, with over 60% of patients experiencing at least a 50% reduction—results that compare favorably to published data for gefapixant, which typically shows 15–20% placebo-adjusted reductions.

Trevi’s first-mover advantage in IPF-related chronic cough is reinforced by robust clinical data and a strong intellectual property position, with patent protection extending into the 2030s. The company’s focused pipeline and capital efficiency—$194.9 million in cash as of Q3 2025, with a projected runway into 2028—support continued development without near-term dilution risk.

However, Trevi remains a single-asset company, and larger rivals possess greater commercial infrastructure and resources. Success will depend on execution in pivotal trials, regulatory approval, and the ability to educate and penetrate a specialist prescriber base.